An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

Pfizer

Status: Completed

Conditions: Advanced Renal Cell Carcinoma

Treatments: Drug: avelumab; Drug: axitinib

Study type: Observational

Funder types: Industry

Identifiers

NCT05394493

B9991044

Details and patient eligibility

About

An observational chart review study to describe the real-world outcomes and use of avelumab in combination with axitinib for treatment of patients with advanced renal cell carcinoma in the United Kingdom.

Enrollment: 130 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

• Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
• Patients with a documented diagnosis of aRCC.
• Patients aged ≥18 years old at the index event date.
• Patient initiated on treatment with avelumab in combination with axitinib ( ≥1 dose) on or after 1st August 2019.

Exclusion criteria

• Patients meeting any of the following criteria will not be included in the study:
• Patients who received avelumab in combination with axitinib as part of a clinical trial
• Patients initiated on avelumab in combination with axitinib less than 12 months from the end of data collection.
• Patients who are known to have opted out of participation in any research

Trial design

130 participants in 1 patient group

patients with advanced renal cell carcinoma

Treatment:

Drug: avelumab

Drug: axitinib